Therefore, Si-based agent are considered excellent therapeutic agent for symptom relief and sustained remission of UC
Results: The NASH-CRN cohort consisted of 3,353 participants (age 39.9 years, 47.5% Male, 28% children, 60% EUR and 31% AMR ancestry)
#Obesity #MetabolicHealth #GLP1 #Amylin #ClinicalTrials #DrugDevelopment #Endocrinology #PharmaInnovation #NovoNordisk #WeightManagement Novo Nordisk Submits CagriSema NDA for Obesity Treatment Major milestone in obesity therapeutics Novo Nordisk has announced the FDA submission of a New Drug Application (NDA) for CagriSema, a first-in-class, once-weekly injectable combination of: Cagrilintide (2.4 mg) a long-acting amylin analogue Semaglutide (2.4 mg) a GLP-1 receptor agonist This dual-hormone approach targets complementary pathways regulating appetite, satiety, and energy balance, marking a potential new era in obesity treatment
Hypothyroidism may result in the following symptoms : Weight gain Muscle soreness, weakness Headaches High cholesterol Constipation Fatigue Brittle hair and nails Dry or scaly skin Impaired cognition Enlarged thyroid (goiter) Cold sensitivity Depression Irregular menstruation Low libido Seeking Treatment Hypothyroidism is a complex condition with multiple possible root causes and a host of symptoms that do not occur in every patient
View mutual connections with John or New to LinkedIn
